EP2136822A1 - Utilisation de solutions ioniques isoosmotiques a base d'eau de mer pour la fabrication de dispositifs medicaux pour la prevention des complications du rhume courant ou du syndrome grippal - Google Patents
Utilisation de solutions ioniques isoosmotiques a base d'eau de mer pour la fabrication de dispositifs medicaux pour la prevention des complications du rhume courant ou du syndrome grippalInfo
- Publication number
- EP2136822A1 EP2136822A1 EP08805714A EP08805714A EP2136822A1 EP 2136822 A1 EP2136822 A1 EP 2136822A1 EP 08805714 A EP08805714 A EP 08805714A EP 08805714 A EP08805714 A EP 08805714A EP 2136822 A1 EP2136822 A1 EP 2136822A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- seawater
- common cold
- isoosmotic
- influenza
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
- A61K35/08—Mineral waters; Sea water
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/16—Fluorine compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/18—Iodine; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
Definitions
- the invention relates to the use of isoosmotic ion solutions based on seawater for the preparation of medical devices for the prevention of complications of common cold or influenza-like illness.
- solution or isoosmotic ion composition based on seawater is meant any solution based on seawater, that is to say containing more than 30% by weight of seawater, preferably more than 75% by weight of seawater, which has an osmolarity of 250 to 350 mOsm / kg, preferably 305 to 315 mOs / kg.
- This definition does not include the so-called physiological solutions which contain, as ionic species, only Na and Cl ions and optionally Se.
- aqueous ionic solutions of the kind in question, enriched with potassium for use in the treatment and washing of the eye as well as for use as a rinsing product for contact lenses.
- These solutions and their uses are described in particular in patents FR2843029 and FR2803205.
- the common or common cold is the infectious, contagious and viral disease of which the human being suffers the most frequently. On average the adult suffers from common cold 2 to 4 times a year and the child can experience up to 12 episodes of common cold a year.
- the common cold is accompanied by nasal symptoms such as tingling in the nasal cavity, sneezing, more or less rhinorrhea and a feeling of stuffy nose but also sore throat, fever and a general malaise that can lead to absenteeism.
- the common cold is a rhinovirus disease with spontaneous remission after about a week with a residual cough that can last up to three weeks. Patients with influenza-like illness have similar symptomatology, although the family of viruses involved is not the same.
- the Applicant Company has unexpectedly and surprisingly found that the daily administration by spraying or nasal misting of an isoosmotic ionic solution based on seawater during and after an episode of common cold or influenza-like illness makes it possible to prevent complications, to avoid relapses, to reduce the number and frequency of common cold episodes and to improve the general state of patients more quickly while avoiding the use of medication.
- the present invention relates to the use of an isoosmotic solution based on seawater for the manufacture of a medical device intended for the administration by spraying or nasal misting of said solution, in patients in phase remission of the common cold or influenza-like illness, or in patients suffering from the common cold or influenza-like illness, to prevent and / or treat complications of the common cold or flu-like illness.
- the medical device is a container with a spray cannula or nasal misting containing said isoosmotic solution based on seawater.
- the invention is intended both for the treatment of adult patients and children or infants.
- the solution when the patient is adult, the solution is applied by nasal spray.
- an application by nasal misting is preferred.
- the number of daily nasal sprays or fogging mentioned refers to the number per nasal cavity.
- the isoosmotic ionic solution based on seawater has:
- the isoosmotic solution based on seawater used in accordance with the invention has the following characteristics: pH of 7.8 to 8.4, dry matter content of 1 to 2% by weight. weight, osmolarity of 305 to 315 mOsm / kg and the following chemical constitution in the main elements:
- Mg ++ for Mg ++ , from 1200 to 1500 mg / l, for Ca ++ , from 300 to 400 mg / l,
- the isoosmotic solution based on seawater used in accordance with the invention has the following characteristics:
- K + for K + , from 4500 to 6500, preferably from 5000 to 6000 mg / l;
- Mg ++ for Mg ++ , from 50 to 1300, preferably from 100 to 500 mg / l;
- Ca ++ for Ca ++ , from 20 to 350, preferably from 40 to 200 mg / l;
- the seawater-based solution also contains other elements such as bromine (Br), preferably at least 50 mg / l, aluminum (Al), fluorine (F), iodine (I), iron (Fe), zinc (Zn), copper
- bromine preferably at least 50 mg / l
- aluminum Al
- fluorine F
- iodine I
- iron Fe
- zinc Zn
- copper copper
- composition of elements other than sodium, potassium, chlorides, calcium and magnesium is qualitatively and quantitatively identical to that of seawater.
- the ionic composition of the solutions implemented in accordance with the invention is that of seawater.
- Table A gives the composition of the seawater as it appears on page F 163 of Handbook of Chemistry and Physics 63rd edition, 1982-1983, CRC PRESS.
- the pH of the seawater is 8-9. It is also known (IFREMER, Coastal Environment and Marine Environment Management Department) that the osmolality of seawater is greater than 1000 mOsm / kg.
- the ionic solutions used according to the invention are devoid of any preservative or stabilizing agent. This last advantage is of great importance. Indeed, the preservatives and / or stabilizers present in most synthetic ionic solutions, cause more or less long-term side effects. However, according to the invention, the ionic solution is administered over periods of time ranging from two weeks to several months, or even years.
- the invention also relates to the use of an isoosmotic seawater-based solution for the preparation of a medicament for nasal spray or mist administration in patients suffering from common cold or flu-like illness. , or in phase remission of the common cold or influenza-like illness to prevent and / or treat complications of common cold or flu-like illness.
- Said medicament may contain, in addition to the ionic solution based on seawater, pharmaceutically acceptable excipients.
- the drug is devoid of preservative or stabilizer.
- the solution in patients in the phase of remission of common cold or influenza-like illness, is administered daily, at least once a day and more preferably three times a day apart from any episode of common cold or of influenza-like illness, for at least one week, preferably for at least two weeks
- the solution is administered, in patients suffering from common cold or influenza-like illness, at the rate of 2 to 9, preferably from 3 to 8, and still more preferably from 4 to 6 daily applications during the whole episode of cold or influenza-like illness then, in the remission phase, at a rate of 1 to 3 daily sprays for at least two weeks, it being understood that, following the remission, the dose is decreased.
- the isoosmotic ionic solution used in accordance with the invention has no side effect, which could notably be related to the presence of stabilizers, it can be used daily throughout the year, preferably throughout the year. epidemiological period.
- the invention also relates to the use as previously described according to which said solution is administered during the common cold or influenza-like illness, without any other medication being administered or during the during the preventive phase, that is to say during the treatment of the common cold or influenza-like illness, or the following weeks.
- the treatment of patients in remission of common cold or influenza-like illness, or of patients suffering from the common cold or influenza-like illness can be done without administering any of the agents chosen from the group comprising an antibiotic, an antipyretic, a mucolytic, an anti-inflammatory, an anti-infective, a nasal decongestant, an anti-tussif and mixtures thereof.
- the solution is administered daily throughout the year, with at least one daily spraying or misting, and at least 2, preferably at least 3 , and more preferably at least 6, daily spraying or misting during epidemiological episodes of common cold or influenza-like illness.
- the iso-osmotic ionic solutions used in accordance with the invention can be prepared by electrodialysis of seawater. More particularly, successively: the raw material is extracted from the seawater.
- this water is analyzed and decanted, the decanted water is decanted by electrodialysis until an osmolality of between 250 and 350 mOsm / kg is obtained, preferably between 305 and 315 mOsm / kg, the ionic concentrations are adjusted. by selective electrodialysis, it is filtered and the product is optionally stored under sterile conditions.
- EXAMPLE We use in this example on the one hand an isoosmotic ionic solution marketed by the company GOEMAR under the trademark PHYSIOMER® which is 100% natural seawater, deodized undiluted, sterile and without preservatives, and other part another isoosmotic ionic solution 100% natural seawater enriched in potassium, sterile which is marketed by the company GOEMAR under the brand SEROPHTA®.
- the PHYSIOMER® solution used in this example is contained in a bottle provided with a spray cannula (PHYSIOMER® Spray) or in a bottle equipped with a jet cannula (PHYSIOMER® Normal jet).
- a spray cannula PHYSIOMER® Spray
- a jet cannula PHYSIOMER® Normal jet
- SEROPHTA® solution is contained in a bottle equipped with a spray cannula (SEROPHTA® Spray).
- Visit 1 establishment of diagnosis, inclusion in the study, severity of nasal symptoms, taking medication
- Visit 2 control of the condition, severity of the nasal symptoms, possibly change of drugs, appreciation of the effectiveness by the doctor and by the patient, safety
- Visit 3 medical status-recurrence, assessment of patient effectiveness, safety
- Visit 4 final control of the condition, severity of the nasal symptoms, appreciation of the effectiveness by the doctor and by the patient, safety.
- the qualitative assessment of dry cough has been transposed on a numerical scale as follows:
- the nasal obstruction has been transposed on a numerical scale as follows:
- Medications have been indicated, including antipyretic, anti-infectious, nasal and mucolytic decongestants.
- the number of patients in group 4 (control) taking antipyretics at visits 3 and 4 is significantly higher than in groups 1, 2 or 3.
- the number of patients in group 4 (control) taking nasal decongestants at visit 4 is significantly higher than that of groups 1, 2 or 3.
- the reoccurrence of the disease was measured by determining the percentage of patients indicating days of illness during the prevention phase, ie between weeks 4 and 12, and counting the number of days children did not not been to school because of their state of health. The percentage of children who have been sick since the previous visit is shown in Table 10 and the results are shown in Figure 10:
- the isoosmotic solutions according to the invention represent an effective solution for the prevention of complications of the common cold. They allow a faster resolution of nasal symptoms, a reduced consumption of drugs, a faster improvement of the general state and also allow to limit the number of days of absence from school.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0703042A FR2915389B1 (fr) | 2007-04-26 | 2007-04-26 | Utilisation de solutions ioniques isoosmotiques a base d'eau de mer pour la fabrication de dispositifs medicaux pour la prevention des complications du rhume courant |
PCT/FR2008/050760 WO2008152265A1 (fr) | 2007-04-26 | 2008-04-25 | Utilisation de solutions ioniques isoosmotiques a base d'eau de mer pour la fabrication de dispositifs medicaux pour la prevention des complications du rhume courant ou du syndrome grippal |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2136822A1 true EP2136822A1 (fr) | 2009-12-30 |
Family
ID=38723970
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP08805714A Ceased EP2136822A1 (fr) | 2007-04-26 | 2008-04-25 | Utilisation de solutions ioniques isoosmotiques a base d'eau de mer pour la fabrication de dispositifs medicaux pour la prevention des complications du rhume courant ou du syndrome grippal |
Country Status (8)
Country | Link |
---|---|
US (1) | US20100151044A1 (fr) |
EP (1) | EP2136822A1 (fr) |
KR (1) | KR20100017239A (fr) |
CN (1) | CN101678048A (fr) |
CA (1) | CA2683701A1 (fr) |
FR (1) | FR2915389B1 (fr) |
RU (1) | RU2519671C2 (fr) |
WO (1) | WO2008152265A1 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2971713B1 (fr) * | 2011-02-18 | 2019-03-29 | Laboratoire De La Mer | Solution ionique aqueuse contenant de l'eau de mer et au moins un compose originellement non miscible a l'eau de mer. |
FR2994389B1 (fr) * | 2012-08-10 | 2014-10-10 | De La Mer Laboratoire | Composition pour le lavage ou le traitement des cavites naso-sinusiennes |
EP2985019B1 (fr) | 2014-08-16 | 2021-10-20 | Church & Dwight Co., Inc. | Composition nasale ayant des propriétés antivirales |
EP2985027B1 (fr) | 2014-08-16 | 2021-03-31 | Church & Dwight Co., Inc. | Composition nasale renfermant un mélange d'acides hyaluroniques et une solution saline |
FR3056911B1 (fr) * | 2016-10-03 | 2019-07-19 | Ys Lab | Composition aqueuse derivee d’eau de mer et d’algues marines |
RU2637438C1 (ru) * | 2016-12-28 | 2017-12-04 | Ирина Евгеньевна Куранчева | Средство для промывания носовой полости, носоглотки и полости рта |
KR102227420B1 (ko) | 2017-06-30 | 2021-03-15 | 대봉엘에스 주식회사 | 비강 세정용 조성물 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2688133A1 (fr) * | 1992-03-06 | 1993-09-10 | Plantes Tropicales Lab | Composition d'hygiene a base d'eau de mer. |
FR2780285B1 (fr) * | 1998-06-29 | 2001-10-05 | Goemar Lab Sa | Utilisation de solutions salines isoosmotiques, leur procede de preparation et medicaments anti-inflammatoires a base de ces solutions |
FR2780284B1 (fr) * | 1998-06-29 | 2001-10-05 | Goemar Lab Sa | Utilisation de solutions salines isoosmotiques, leur procede de preparation et medicaments cerumenolytiques a base de ces solutions |
FR2796844B1 (fr) * | 1999-07-27 | 2003-05-23 | Goemar Lab Sa | Nouvelle utilisation de solutions salines hypoosmotiques et medicament a base de ces solutions |
FR2803205B1 (fr) * | 1999-12-31 | 2002-10-18 | Goemar Lab Sa | Solutions ioniques aqueuses et leurs utilisations notamment en ophtalmologie |
FR2843029B1 (fr) * | 2002-08-02 | 2006-05-26 | Goemar Lab Sa | Solution de rincage pour lentilles de contact |
US7097852B1 (en) * | 2003-05-09 | 2006-08-29 | Soto Jose A | Solution comprising sea water as expectorant and virucidal for the treatment of respiratory diseases and method to use and develop |
-
2007
- 2007-04-26 FR FR0703042A patent/FR2915389B1/fr active Active
-
2008
- 2008-04-25 CA CA002683701A patent/CA2683701A1/fr not_active Abandoned
- 2008-04-25 EP EP08805714A patent/EP2136822A1/fr not_active Ceased
- 2008-04-25 CN CN200880013468A patent/CN101678048A/zh active Pending
- 2008-04-25 WO PCT/FR2008/050760 patent/WO2008152265A1/fr active Application Filing
- 2008-04-25 KR KR1020097024310A patent/KR20100017239A/ko not_active Application Discontinuation
- 2008-04-25 US US12/596,955 patent/US20100151044A1/en not_active Abandoned
- 2008-04-25 RU RU2009143590/15A patent/RU2519671C2/ru active
Non-Patent Citations (2)
Title |
---|
See also references of WO2008152265A1 * |
SLAPAK IVO ET AL: "Efficacy of isotonic nasal wash (seawater) in the treatment and prevention of rhinitis in children.", ARCHIVES OF OTOLARYNGOLOGY--HEAD & NECK SURGERY JAN 2008 LNKD- PUBMED:18209140, vol. 134, no. 1, January 2008 (2008-01-01), pages 67 - 74, ISSN: 0886-4470 * |
Also Published As
Publication number | Publication date |
---|---|
US20100151044A1 (en) | 2010-06-17 |
WO2008152265A1 (fr) | 2008-12-18 |
RU2009143590A (ru) | 2011-06-10 |
KR20100017239A (ko) | 2010-02-16 |
CN101678048A (zh) | 2010-03-24 |
FR2915389A1 (fr) | 2008-10-31 |
FR2915389B1 (fr) | 2012-12-21 |
CA2683701A1 (fr) | 2008-12-18 |
RU2519671C2 (ru) | 2014-06-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Slaughter et al. | The clinical toxicology of sodium hypochlorite | |
EP2136822A1 (fr) | Utilisation de solutions ioniques isoosmotiques a base d'eau de mer pour la fabrication de dispositifs medicaux pour la prevention des complications du rhume courant ou du syndrome grippal | |
JP2020500864A5 (fr) | ||
EP2068896B1 (fr) | Solutions ioniques hypertoniques a base d'eau de mer non diluee, leur utilisation en tant que compositions pharmaceutiques ou medicaments et pour la preparation de medicaments destines au traitement de la congestion nasale | |
Bogacz et al. | Enteric-coated aspirin bezoar: elevation of serum salicylate level by barium study | |
EP2618844A2 (fr) | Composition orale et procédé de formation et d'utilisation de celle-ci | |
JP2024026871A (ja) | 慢性便秘症を治療するための医薬組成物 | |
JP2006347958A (ja) | 咽頭粘膜抗炎症スプレー剤 | |
BE1023090B1 (fr) | Composition | |
US20170020946A1 (en) | Analgesic compositions and methods of use | |
BE1011395A5 (fr) | Composition et utilisation. | |
Rao | Recurrent aphthous stomatitis: a review | |
JP2003159028A (ja) | 花粉症治療用食品 | |
Southwood et al. | Ingestion of potassium permanganate crystals by a three‐year‐old boy | |
JP2006206461A (ja) | アレルギー疾患の予防・治療用組成物 | |
JP2004203863A (ja) | 抗糖尿病用組成物 | |
Tiwari et al. | Case report-a rare survival of 2, 4-D (ethyl ester) ingestions | |
FR2967069A3 (fr) | Formulations | |
EP4240387A1 (fr) | Nouvelle composition thérapeutique à base d'huiles essentielles à faibles doses | |
WO2011139237A1 (fr) | Composition pour le traitement d'infections par helicobacter pylori (h. pylori) | |
WO2004032823A2 (fr) | Composition de traitement et de rehydratation pour limiter les effets secondaires des gastro-enterites chez l'adulte | |
IT201900000268A1 (it) | composizioni per il trattamento della costipazione | |
JP2008031110A (ja) | 痛みの予防又は緩和剤 | |
US20130059918A1 (en) | Throat irritation relief beverage | |
AU2002225823A1 (en) | Method for treating HIV |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20091006 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR |
|
DAX | Request for extension of the european patent (deleted) | ||
17Q | First examination report despatched |
Effective date: 20100914 |
|
APBK | Appeal reference recorded |
Free format text: ORIGINAL CODE: EPIDOSNREFNE |
|
APBN | Date of receipt of notice of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA2E |
|
APBR | Date of receipt of statement of grounds of appeal recorded |
Free format text: ORIGINAL CODE: EPIDOSNNOA3E |
|
APAF | Appeal reference modified |
Free format text: ORIGINAL CODE: EPIDOSCREFNE |
|
APAF | Appeal reference modified |
Free format text: ORIGINAL CODE: EPIDOSCREFNE |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R003 |
|
APBT | Appeal procedure closed |
Free format text: ORIGINAL CODE: EPIDOSNNOA9E |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED |
|
18R | Application refused |
Effective date: 20190611 |